Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

McGill University

$35,000.00

Mechanism of Egr-1 control of cardiac calcium homeostasis

EF 2009-10

Résumé
) Egr-1 overexpressing cardiac cells have repressed calcium dynamics linked to reduced calsequestrin 2 (CSQ2) expression (Kasneci et al App 1). We found Egr-1 to repress CSQ2 expression by a novel mechanism. Egr-1 binds rat and mouse CSQ2 promoter DNA at a 165 bp region that is >75% homologous between the 2 species and contains Egr-1 and SP1 consensus sites overlapping a CpG island. Egr-1 is known to bind to SP1, p300/CBP and casein kinase II, is phosphorylated by PKA, PKC and CKII and acetylated by p300/CBP. Whether these modifications or interactions promote activation or repression depends upon the promoter analyzed and tissue/cell type used. We hypothesize that Egr-1 displaces activating SP1 to repress CSQ2. Because Egr-1's action is context dependent we hypothesize that the Egr-1 modifications and the Egr-1 complexes formed with existing protein:DNA complexes and/or DNA/chromatin modifiers at the repressed CSQ2 promoter are particular to cardiac cells. ) In this proposal we will modulate Egr-1 and SP1 levels, define their interacting domains, define how they interact at CSQ2 promoter DNA, alter Egr-1 phosphorylation and acetylation and DNA methylation of CSQ2 DNA and measure the impact on CSQ2 expression and Egr-1:DNA binding. We will use biotinylated oligonucleotide and TAP-tag capture techniques to isolate new cardiac-specific Egr-1 binding partners and use proteomics to identify them. Validation of interactions will use biochemical and live cell techniques. ) How transcription factors in general and Egr-1 in particular repress gene expression is not well understood. Egr-1 networking with other transcription factors and DNA modifying proteins at the DNA interface represses CSQ2 by a novel mechanism. In this proposal we will identify the repression mechanism of a protein of widespread importance (Egr-1) to a target of physiological relevance (CSQ2).
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
171274-2009
Name nom
Chalifour, Lorraine
Department département
Medicine, Faculty of
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2009
Award amount
35000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
33
Committee name en
Molec. & Develop. Genetics
Committee name fr
Gén. moléculaire et dévelop.
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5303
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Gene regulation
Research subject fr
Régulation des gènes
Partie
1
Nb partie
3
Application title
Mechanism of Egr-1 control of cardiac calcium homeostasis
Keyword
NA
Application summary
) Egr-1 overexpressing cardiac cells have repressed calcium dynamics linked to reduced calsequestrin 2 (CSQ2) expression (Kasneci et al App 1). We found Egr-1 to repress CSQ2 expression by a novel mechanism. Egr-1 binds rat and mouse CSQ2 promoter DNA at a 165 bp region that is >75% homologous between the 2 species and contains Egr-1 and SP1 consensus sites overlapping a CpG island. Egr-1 is known to bind to SP1, p300/CBP and casein kinase II, is phosphorylated by PKA, PKC and CKII and acetylated by p300/CBP. Whether these modifications or interactions promote activation or repression depends upon the promoter analyzed and tissue/cell type used. We hypothesize that Egr-1 displaces activating SP1 to repress CSQ2. Because Egr-1's action is context dependent we hypothesize that the Egr-1 modifications and the Egr-1 complexes formed with existing protein:DNA complexes and/or DNA/chromatin modifiers at the repressed CSQ2 promoter are particular to cardiac cells. ) In this proposal we will modulate Egr-1 and SP1 levels, define their interacting domains, define how they interact at CSQ2 promoter DNA, alter Egr-1 phosphorylation and acetylation and DNA methylation of CSQ2 DNA and measure the impact on CSQ2 expression and Egr-1:DNA binding. We will use biotinylated oligonucleotide and TAP-tag capture techniques to isolate new cardiac-specific Egr-1 binding partners and use proteomics to identify them. Validation of interactions will use biochemical and live cell techniques. ) How transcription factors in general and Egr-1 in particular repress gene expression is not well understood. Egr-1 networking with other transcription factors and DNA modifying proteins at the DNA interface represses CSQ2 by a novel mechanism. In this proposal we will identify the repression mechanism of a protein of widespread importance (Egr-1) to a target of physiological relevance (CSQ2).